GlassScriptPhysician profile
Karla A Mcnair
NPI 1467466110
$811.32
in general payments reported to CMS, 2019-2025
20 companies · $255 in 2025
The $255 reported for 2025 was more than what 80% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $13.62 · 2021: $29.99 · 2022: $77.15 · 2023: $76.33 · 2024: $188 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $149.08 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sanofi Pasteur INC. | $143.62 | 2019-2024 | |
| Sage Therapeutics, LLC | $77.52 | 2024-2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $52.58 | 2019 | |
| Exeltis, USA INC. | $49.88 | 2025 | Slynd |
| Shire North American Group INC | $40.71 | 2019 | |
| Mayne Pharma Commercial LLC | $38.33 | 2025 | |
| Alkermes, INC. | $32.62 | 2024 | Aristada, Lybalvi |
| Pfizer INC. | $31.81 | 2019-2024 | |
| Millicent US INC | $22.99 | 2025 | Intrarosa, Femlyv |
| Supernus Pharmaceuticals, INC. | $20.91 | 2025 | Qelbree |
| Organon LLC | $19.46 | 2025 | Nexplanon |
| Tris Pharma INC | $19.42 | 2023 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $18.69 | 2025 | Spravato |
| Dexcom, INC. | $17.58 | 2025 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $17.51 | 2022 | |
| Seqirus USA INC | $17.14 | 2025 | Flucelvax, Fluad |
| Agios Pharmaceuticals, INC. | $14.40 | 2024 | Pyrukynd |
| Qiagen, LLC | $13.79 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Mcnair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.